Galapagos (GXEA) Stock Overview
A biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for GXEA from our risk checks.
GXEA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Galapagos NV Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €28.40 |
| 52 Week High | €31.40 |
| 52 Week Low | €19.90 |
| Beta | 0.041 |
| 1 Month Change | 2.90% |
| 3 Month Change | 4.41% |
| 1 Year Change | 25.66% |
| 3 Year Change | -27.92% |
| 5 Year Change | -67.73% |
| Change since IPO | -35.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| GXEA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -4.1% | -2.8% |
| 1Y | 25.7% | -11.7% | 8.9% |
Return vs Industry: GXEA exceeded the German Biotechs industry which returned -11.4% over the past year.
Return vs Market: GXEA exceeded the German Market which returned 10% over the past year.
Price Volatility
| GXEA volatility | |
|---|---|
| GXEA Average Weekly Movement | 4.5% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: GXEA has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: GXEA's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 558 | Henry Gosebruch | www.glpg.com |
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l.
Galapagos NV Fundamentals Summary
| GXEA fundamental statistics | |
|---|---|
| Market cap | €1.88b |
| Earnings (TTM) | -€443.87m |
| Revenue (TTM) | €286.92m |
Is GXEA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GXEA income statement (TTM) | |
|---|---|
| Revenue | €286.92m |
| Cost of Revenue | €494.12m |
| Gross Profit | -€207.20m |
| Other Expenses | €236.68m |
| Earnings | -€443.87m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Feb 23, 2026
| Earnings per share (EPS) | -6.74 |
| Gross Margin | -72.21% |
| Net Profit Margin | -154.70% |
| Debt/Equity Ratio | 0% |
How did GXEA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/21 09:52 |
| End of Day Share Price | 2026/01/21 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Galapagos NV is covered by 30 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xue Chen | Barclays |
| Emily Field | Barclays |
| Patrick Trucchio | Berenberg |